Bcli News Today

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Get Free Report) was the recipient of a significant increase in short interest in April. As of April 15th, there was short interest totalling 1,990,000 shares, an increase of 48.5% from the March 31st total of 1,340,000 shares. Based on an average daily volume of 987,100 shares, the short-interest […]

By Denny Jacob BrainStorm Cell Therapeutics shares rose 7.2% to 35 cents following a submitted special protocol assessment request to the Food and Drug...

Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Free Report) and Tenaya Therapeutics (NASDAQ:TNYA – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, dividends, risk, profitability and institutional ownership. Institutional & Insider Ownership 21.0% of […]

StockNews.com assumed coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI – Free Report) in a research note published on Wednesday morning. The firm issued a hold rating on the biotechnology company’s stock. Brainstorm Cell Therapeutics Stock Performance Shares of NASDAQ:BCLI opened at $0.39 on Wednesday. Brainstorm Cell Therapeutics has a one year low of $0.13 […]

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Get Free Report) saw a significant decline in short interest in the month of January. As of January 15th, there was short interest totalling 2,390,000 shares, a decline of 43.2% from the December 31st total of 4,210,000 shares. Based on an average trading volume of 2,600,000 shares, the days-to-cover […]

StockNews.com began coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI – Free Report) in a research note issued to investors on Tuesday. The brokerage issued a hold rating on the biotechnology company’s stock. Separately, Maxim Group lowered Brainstorm Cell Therapeutics from a buy rating to a hold rating in a research report on Thursday, September […]

StockNews.com began coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI – Free Report) in a research report report published on Tuesday. The brokerage issued a hold rating on the biotechnology company’s stock. Separately, Maxim Group lowered shares of Brainstorm Cell Therapeutics from a buy rating to a hold rating in a report on Thursday, September […]

StockNews.com initiated coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI – Free Report) in a report issued on Sunday morning. The brokerage issued a hold rating on the biotechnology company’s stock. Separately, Maxim Group downgraded shares of Brainstorm Cell Therapeutics from a buy rating to a hold rating in a research report on Thursday, September […]

StockNews.com assumed coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI – Free Report) in a research note released on Saturday. The firm issued a hold rating on the biotechnology company’s stock. Separately, Maxim Group cut Brainstorm Cell Therapeutics from a buy rating to a hold rating in a research note on Thursday, September 28th. Check […]

By Ben Glickman Shares of Brainstorm Cell Therapeutics were higher Tuesday after the company secured a patent for its technology used for treating ALS. The...